

1628

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to Commissioner for Patents, Washington, DC 20231, on the date shown below

Dated 2/4/03

Signature

(Anna P. Lucey)

Docket No.: AS 00-P01-47

TECH CENTER 1600 2003

FEB 07 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Faull et al.

Application No.: 09/889515

Group Art Unit: 1626

Filed: October 10, 2001

Examiner: Wright, Sonya N.

For: ANTI-INFLAMMATORY INDOLE
DERIVATIVES

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents should one or more of the documents be used against the claims of the present application.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P01-471.

Dated:

Respectfully submitted,

By 

David P. Halstead, Ph.D.

Registration No.: 44,735

ROPES & GRAY

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys for Applicant

Form PTO SB 08

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

Use several sheets if necessary.

Docket Number (Optional)
ASZD-P01-471Application Number
09 889,515

Applicant

Faull et al.

Filing Date

October 10, 2001

Group Art Unit
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED
FEB 07 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
	AA	DE 298 913 a5	3/1992	Germany				X
	AB	EP 0 189 690	8/6/86	EPO				
	AC	EP 0 419 049 A1	3/27/91	EPO				
	AD	EP 0 480 659 A2	4/15/92	EPO				
	AE	EP 0 535 923 A1	4/7/93	EPO				
	AF	EP 0 535 924 A1	4/7/93	EPO				
	AG	EP 0 535 925 A1	4/7/93	EPO				
	AH	EP 0 535 926 A1	4/7/93	EPO				
	AI	EP 0 639 573 A1	2/22/95	EPO			Abstract	
	AJ	EP 0 822 185	2 4 98	EPO				
	AK	EP 0 275 667	7/27/98	EPO				
	AL	FR 2 565 981	12/20/85	France			Abstract	
	AM	JP 63284177	11/21/88	Japan			Abstract	
	AN	JP 4273857	9/30/92	Japan			Abstract	
	AO	WO 86 00896	2/13/86	WIPO				
	AP	WO 92 04343	3/19/92	WIPO				
	AQ	WO 93 16069	8/19/93	WIPO				
	AR	WO 93 20078	10/14/93	WIPO				
	AS	WO 94 14434	7/7/94	WIPO				
				WIPO				

Form PTO SB 08

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

FEB 17 2003

Docket Number (Optional)

ASZD-P01-471

Application Number

09 889,515

Applicant

Faull et al.

Filing Date

October 10, 2001

Group Art Unit

1626

AW	WO 97/13615	4/10/97	WIPO				
AX	WO 97/30704	8/28/97	WIPO				
AY	WO 97/35572	10/2/97	WIPO				
AZ	WO 98/06703	2/19/98	WIPO				

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

BA	Berman, J.W. et al. Localization of Monocyte Chemoattractant Peptide-1 Expression in the Central Nervous System in Experimental Autoimmune Encephalomyelitis and Trauma in the Rat. <i>J. Immunol.</i> 156, 3017-3023 (1996).
BB	Bobosik, V. & Krutosikova, A. Synthesis of N-Phenylsulfonyl Protected Furo[3,2-b]Pyrroles. <i>Collect. Czech. Chem. Commun.</i> 59, 499-502 (1994).
BC	Dandarova, M. ¹³ C NMR Spectra of Some Substituted Furo[3,2-b]pyrroles. <i>Magnetic Resonance Chem.</i> 28, 830-831 (1990).
BD	Deleuran, M. et al. Localization of monocyte chemotactic and activating factor (MCAF/MCP 1) in psoriasis. <i>J. Dermatological Sci.</i> 13, 228-236 (1996).
BE	Grimm, M.C. et al. Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa. <i>J. Leukocyte Biol.</i> 59, 804-812 (June 1996).
BF	Harrison, C.-A. et al. Cyclopenta [b] indoles. Part 2. Model studies towards the tremorgenic mycotoxins. <i>J. Chem. Soc. Perkin Trans.</i> 1131-1136 (1995).
BG	Hartman, G.D. & Halczenko, W. The Synthesis of 5-Alkylaminomethylthieno[2,3-b]pyrrole-5-sulfonamides. <i>Heterocycles</i> 29, 1943-1949 (1989).
BH	Jones, M.L. et al. Potential Role of Monocyte Chemoattractant Protein 1 (MCP-1) in Monocyte/Macrophage-Dependent IgA Immune Complex Alveolitis in the Rat. <i>J. Immunol.</i> 149, 2147-2154 (15 Sept. 1992).
BI	Kataoka, K. et al. Homopiperazines as cell migration inhibitors. <i>Chemical Abstracts</i> , Columbus Ohio, US 123, 667 (2 October 1995).
BJ	Koch, A.E. et al. Enhanced Production of Monocyte Chemoattractant Protein-1 Rheumatoid Arthritis. <i>J. Clin. Invest.</i> 90, 772-779 (Sept. 1992).
BK	Korobchenko, L.V. et al. Synthesis and antiviral activity of pyrrolecarboxylic acids and their derivatives. <i>Chemical Abstracts</i> , Columbus, Ohio, Access Number: 119,62465 (1999).
BL	Krutosikova, A. & Dandarova, M. Substituted Vinyl Azides in Synthesis of Furo[3,2-b:4,5-b']-Dipyrroles and Pyrrolo[2',3':4,5]furo[3,2-c]Pyridines. <i>Heterocycles</i> 37, 1695-1700 (1994).
BM	Krutosikova, A. & Dandarova, M. Reactions of Methyl 2-Formylfuro[3,2-b]pyrrole-5-carboxylates. <i>Chem. Papers</i> 50, 72-76 (1996).

11/18/1992

Form PTO SB 08

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)
ASZD-P01-471Application Number
09 889,515

Applicant

Faull et al.

Filing Date

October 10, 2001

Group Art Unit

1626

BO	Krutosikova, A. et al. Condensed O-, N-Heterocycles by the Transformation of Azidoacrylates. <i>Chemical Monthly</i> 123, 807-815 (1992).
BP	Krutosikova, A. et al. Derivatives of Furo[3,2-b]Pyrrole. <i>Collect. Czech. Chem. Commun.</i> 59, 473-481 (1994).
BQ	Krutosikova, A. et al. Substituted Vinyl Azides in the Synthesis of Condensed Nitrogen Heterocycles. <i>Chem. Papers</i> 48, 268-273 (1994).
BR	Krutosikova, A. et al. Synthesis and Reactions of Furo[3,2-b]Pyrrole Type Aldehydes. <i>Collect. Czech. Chem. Commun.</i> 58, 2139-2149 (1993).
BS	Krutosikova, A. et al. Synthesis and Reactions of Furo[2,3-b]pyrroles. <i>Molecules</i> 2, 69-79 (1997).
BT	Murakami, Y. et al. Direct Regioselective Vinylation of Indoles Using Palladium (II) Chloride. <i>Heterocycles</i> 22, 1493-1496 (1984).
BU	Rosenmund, P. et al. Decarboxylations of Some 1-Alkyl-2-carboxy-3-indolacetic Acids and Synthesis of a 5-Thiocyanato-2,3-dihydroindole. <i>Chem. Ber.</i> 108, 3538-3542 (1975). - Abstract only.
BV	Troschutz, R. & Hoffmann, A. Synthesis of Substituted 3-Amino-4-cyano-1-oxo-1,2,5,10-tetrahydroazepino[3,4-b]indoles. <i>J. Heterocyclic Chem.</i> 34, 1431 (1997).
BW	Yokoyama, Y. et al. Palladium-Catalyzed Cross-Coupling Reaction: Direct Allylation of Aryl Bromides with Allyl Acetate. <i>Tetrahedron Letters</i> 26, 6457-6460 (1985).
BX	Yokoyama, Y. et al. New Synthetic Method for Dehydrotryptophan Derivatives. Synthesis Studies on Indoles and Related Compounds. XXIV. <i>Chem. Pharm. Bull.</i> 42, 832-838 (1994).
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE